Atrial Fibrillation Clinical Trial
Official title:
Medical Economical Evaluation of the Ablation by Catheter of the Atrial Tissue in the Treatment of the Atrial Fibrillation
The atrial fibrillation is the most frequent confusions of the heart rhythm: his preValencia increases with the age, and the investigators consider that beyond 65 years, 5 % of the population is affected by this arrhythmia. It entails a greater risk of morbidity (thromboembolic accident and cardiac insufficiency) and of cardiovascular mortality (mortality increased by a factor 1,7 - 2) independents of the causal pathology or the associated risk factors. For all these reasons, it raises a real problem of public health.
The atrial fibrillation is the most frequent confusions of the heart rhythm: his preValencia
increases with the age, and we consider that beyond 65 years, 5 % of the population is
affected by this arrhythmia. It entails a greater risk of morbidity (thromboembolic accident
and cardiac insufficiency) and of cardiovascular mortality (mortality increased by a factor
1,7 - 2) independents of the causal pathology or the associated risk factors. For all these
reasons, it raises a real problem of public health.
The medical treatment of PAROXYSTIC or persistent atrial fibrillation associates
antiarrythmic and anticoagulant. The purpose of it is to maintain the sinusal rhythm and to
prevent the thromboembolic complications. The success rate of the treatment antiarrythmic is
disappointing, not exceeding, on average, 50 % with 1 year. In addition the incidence of the
side effects of these molecules as that of the anticoagulants is far from being negligible.
Other not-pharmacological therapeutic alternatives were proposed among resistant patients,
such final cardiac stimulation whose results are not currently very convincing. Ablation by
catheter is, except the surgery whose indications are exceptional, the only curative
treatment of AF. The complications of the procedure are rare (1 to 2%), but they can be
severe. The indication of ablation for which there is currently a consensus is that of AF
PAROXYSTIC repeating or persistent, symptomatic, on c?ur normal or pathological, resistant
to at least 1 major treatment antiarrythmic. The effectiveness of ablation was validated by
many studies within the framework of PAROXYSTIC or persistent AF in very specialized
centers. The diffusion of this mode of treatment is limited in our country where very few
centers practise it because of a long and difficult training of the technique, claiming a
great expertise, but also of the need for human and material means important. The number of
ablations carried out in the consensual indications in 2003 in France was approximately 450.
This figure is very weak compared to the prevalence of this disorder of the rate/rhythm.
This leads in the few centers invested to long withdrawal periods for the patient whom can
reach 4 to 12 months.
Awaited benefit of ablation by catheter:
1. reduction of the costs of health thanks to the suppression of any treatment and with a
reduction of the duration and frequency of the hospitalizations and consultations
2. faster rehabilitation of the patients in the active life.
Principal objectives of this evaluation: medical and economic:
1. medical evaluation of the effectiveness of ablation by radio frequency of AF under
conditions of real practice: persistence of the sinusal rhythm. Ablation should make it
possible to cure 70 % of the treated patients
2. costing of the technique and utilization of the results expressed in avoided costs,
reduction of the stops of work and quality of life, compared with those of the medical
treatment studied retrospectively on 1 year.
Secondary objectives:
1. evaluation of the risk of ablation: complications related to the procedure and inherent
with the treated arrhythmia,
2. evaluation of the quality of life of the treated patients: use of antiarrythmic, the
anticoagulants, questionnaires of quality of life: SF 36, professional renewal of
activity
3. analysis of the impact of the setting in?uvre of the technique of ablation on the
system of care of the various hospital complexes concerned
4. exploratory study of determination of the criteria of success/failure of ablation.
Method:
national, prospective, comprising 1 year of inclusion and 2ans of follow-up but also
retrospective multicentric evaluation over the year preceding ablation, each patient
constituting his own witness. Considering an assumption of success awaited of ablation of
about 70 %, the number of patients included on 1 year will have to be 225 in order to obtain
a precision about ± 6 % in the determination of the success rate of the method under
conditions of real practice. In addition this size of sample will allow an analysis of the
various medico-economic criteria and the construction of a multivariate model of prediction
of the success of ablation according to the characteristics of the patients. It was checked
that this size of sample was perfectly possible taking into account current flows of
patients.
Criteria of inclusion:
old patients from 18 to 80 years presenting F PAROXYSTIC or persistent, symptomatic,
documented (at least 1 episode documented by ECG and/or Holter) and dating of more than 6
months, having repeated under at least 1 major anti-asynchronous treatment.
Awaited results and prospects:
this project will make it possible to appreciate the médico-economic impact of this
therapeutic among patients presenting an allowed indication of ablation. It will provide the
essential information and never yet collected in France on such a scale. It will make it
possible to develop this activity at the hospital level, essential condition with its
development. It will also make it possible to appreciate the operational constraints in term
of need for teams and their distribution on the territory taking into account flows of
patients and the level for necessary technicality. This study will finally make it possible
to determine the predictive elements of therapeutic success and to which type of patients
ablation brings the greatest benefit.
;
Observational Model: Cohort, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
| Completed |
NCT04571385 -
A Study Evaluating the Efficacy and Safety of AP30663 for Cardioversion in Participants With Atrial Fibrillation (AF)
|
Phase 2 | |
| Terminated |
NCT04115735 -
His Bundle Recording From Subclavian Vein
|
||
| Completed |
NCT05366803 -
Women's Health Initiative Silent Atrial Fibrillation Recording Study
|
N/A | |
| Completed |
NCT02864758 -
Benefit-Risk Of Arterial THrombotic prEvention With Rivaroxaban for Atrial Fibrillation in France
|
||
| Recruiting |
NCT05442203 -
Electrocardiogram-based Artificial Intelligence-assisted Detection of Heart Disease
|
N/A | |
| Completed |
NCT05599308 -
Evaluation of Blood Pressure Monitor With AFib Screening Feature
|
N/A | |
| Completed |
NCT03790917 -
Assessment of Adherence to New Oral anTicoagulants in Atrial Fibrillation patiEnts Within the Outpatient registrY
|
||
| Enrolling by invitation |
NCT05890274 -
Atrial Fibrillation (AF) and Electrocardiogram (EKG) Interpretation Project ECHO
|
N/A | |
| Recruiting |
NCT05316870 -
Construction and Effect Evaluation of Anticoagulation Management Model in Atrial Fibrillation
|
N/A | |
| Recruiting |
NCT05266144 -
Atrial Fibrillation Patients Treated With Catheter Ablation
|
||
| Not yet recruiting |
NCT06023784 -
The Impact of LBBAP vs RVP on the Incidence of New-onset Atrial Fibrillation in Patients With Atrioventricular Block
|
N/A | |
| Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
| Recruiting |
NCT04092985 -
Smart Watch iECG for the Detection of Cardiac Arrhythmias
|
||
| Completed |
NCT04087122 -
Evaluate the Efficiency Impact of Conducting Active Temperature Management During Cardiac Cryoablation Procedures
|
N/A | |
| Completed |
NCT06283654 -
Relieving the Emergency Department by Using a 1-lead ECG Device for Atrial Fibrillation Patients After Pulmonary Vein Isolation
|
||
| Recruiting |
NCT05416086 -
iCLAS™ Cryoablation System Post-Market Clinical Follow-up (PMCF) Study
|
N/A | |
| Completed |
NCT05067114 -
Solutions for Atrial Fibrillation Edvocacy (SAFE)
|
||
| Completed |
NCT04546763 -
Study Watch AF Detection At Home
|
||
| Completed |
NCT03761394 -
Pulsewatch: Smartwatch Monitoring for Atrial Fibrillation After Stroke
|
N/A |